Carbidopa And Levodopa Enteral

Introduction Overview

Generic Name

carbidopa and levodopa enteral

Brand Name

Duopa

Dosage Form

Enteral suspension gel delivered via infusion pump through a PEG-J tube into the small intestine

Drug Class

Dopaminergic antiparkinsonism agents

Pharmacokinetics

Absorption:
Duopa is administered as a carbidopa and levodopa enteral suspension gel directly into the jejunum via a surgically implanted percutaneous endoscopic gastrojejunostomy (PEG-J) tube using a portable infusion pump. This delivery bypasses the stomach, avoiding variable gastric emptying and intragastric degradation that can contribute to erratic absorption when levodopa is administered orally. Consequently, Duopa provides more consistent and continuous absorption of levodopa into the systemic circulation. The jejunal delivery allows rapid availability and enhanced bioavailability of levodopa, leading to a more stable plasma concentration profile compared to oral formulations. Clinical studies have demonstrated that continuous jejunal infusion reduces fluctuations in plasma levodopa levels, resulting in decreased motor 'off' periods in Parkinson's disease patients.

Distribution:
After absorption, levodopa crosses the blood-brain barrier via an active transport mechanism, primarily the large neutral amino acid transporter (LAT1), to reach the central nervous system (CNS) where it is converted to dopamine. Carbidopa does not cross the blood-brain barrier but inhibits peripheral aromatic L-amino acid decarboxylase (AADC), reducing peripheral conversion of levodopa to dopamine, increasing the fraction of levodopa delivered to the brain and minimizing peripheral side effects. The volume of distribution for levodopa is approximately 0.9–1.5 L/kg. Levodopa shows moderate plasma protein binding. Factors such as dietary amino acids can compete with levodopa for transport across the gut and blood-brain barrier.

Metabolism:
Levodopa undergoes extensive metabolism in peripheral tissues. It is primarily metabolized by aromatic L-amino acid decarboxylase (AADC) to dopamine and by catechol-O-methyltransferase (COMT) to 3-O-methyldopa. Carbidopa inhibits peripheral AADC, limiting peripheral decarboxylation of levodopa and increasing levodopa half-life and CNS delivery. Metabolites of levodopa include homovanillic acid and vanillylmandelic acid, which are excreted renally. The presence of carbidopa allows for reduced levodopa dosage by preventing premature metabolism.

Elimination:
Levodopa is eliminated primarily via renal excretion of metabolites; less than 1% is excreted unchanged in the urine. The elimination half-life of levodopa when administered with carbidopa ranges from 1.5 to 2 hours but is prolonged with the continuous infusion method used by Duopa. The enteral infusion pump ensures steady plasma drug levels over the 16-hour dosing period, reducing peak-to-trough fluctuations common with oral administration. Continuous infusion also facilitates more predictable elimination kinetics and clinical effect stability. Metabolites are excreted by the kidneys, so renal impairment may necessitate dose adjustments.

Pharmacokinetic parameters may be impacted by factors such as age, hepatic function, concomitant medications, and dietary protein intake, which can affect levodopa transport and metabolism. The controlled infusion through PEG-J tubing helps minimize these variabilities, improving therapeutic outcomes in advanced Parkinson's disease patients.

Dosage Forms

Available Dosage Forms:
Duopa is provided as an enteral suspension gel in a plastic cassette designed for use with the CADD-Legacy 1400 portable infusion pump. Each cassette contains a fixed concentration of carbidopa and levodopa (4.63 mg carbidopa and 20 mg levodopa per mL). The suspension is specifically formulated for administration via a PEG-J tube directly into the small intestine.

Dosages for Adults and Adolescents:
Duopa is indicated for adult patients with advanced Parkinson's disease experiencing motor fluctuations. Initial dosing involves converting existing oral levodopa therapy to the enteral suspension with a 1:4 conversion ratio (oral levodopa mg to mL of Duopa). The daily dose is divided into three components: a morning bolus dose administered rapidly over 10 to 30 minutes to achieve therapeutic plasma levels, a continuous maintenance dose infusion over 16 waking hours at a steady rate, and extra bolus doses (each 1 mL or 20 mg levodopa) available to counteract acute 'off' symptoms.
Day 1 dosing: Morning dose is equivalent to the patient’s previous oral levodopa morning dose; continuous dose covers the remainder of the daily levodopa requirement excluding morning and nighttime doses. Extra bolus doses are titrated in increments of 0.2 mL.
Dose adjustments are individualized based on motor symptom control and adverse effects. The maximum dose corresponds to one cassette over 16 hours, delivering 2000 mg levodopa; maintenance nighttime symptom control is often provided by oral carbidopa/levodopa tablets.

Specific Patient Populations:
- The safety and efficacy of Duopa have not been established in patients under 18 years old.
- Patients with renal or hepatic impairment may require dose adjustments due to altered metabolism and elimination.
- Use in pregnancy and lactation is not well-studied; breastfeeding may be affected as Duopa can reduce milk production.
- Patients with a history of intestinal surgery or ulcers require careful evaluation due to administration via PEG-J tube.
- The enteral suspension formulation is contraindicated in patients who have taken MAO inhibitors within 14 days due to risk of hypertensive crisis.

Storage and Handling:
Duopa cassettes must be stored frozen at -20°C (-4°F) prior to dispensing. Upon dispensing, they should be thawed in a refrigerator at 2°C to 8°C (36°F to 46°F) for up to 96 hours before use. Once removed from refrigeration, the cassette should reach room temperature (~20 minutes) before administration and protected from light. Each cassette is single-use for a maximum of 16 hours only.

Mechanism Of Action

Duopa combines carbidopa and levodopa in an enteral suspension administered directly into the small intestine, optimizing delivery and therapeutic effect in Parkinson's disease. The primary mechanism involves levodopa acting as a biochemical precursor to dopamine, replenishing deficient dopamine levels within the basal ganglia of the brain, which is critical for motor control.

Levodopa crosses the blood-brain barrier via the large neutral amino acid transporter and is enzymatically decarboxylated by aromatic L-amino acid decarboxylase (AADC) in dopaminergic neurons to produce dopamine. This dopamine replacement ameliorates motor symptoms by stimulating dopamine receptors in the striatum, restoring normal neural transmission pathways disrupted by dopaminergic neuron loss in Parkinson's disease.

Carbidopa serves a key adjunctive role by selectively inhibiting peripheral AADC, preventing the premature peripheral conversion of levodopa to dopamine outside the central nervous system. This increases the bioavailability of levodopa to the brain and decreases peripheral side effects such as nausea, cardiovascular instability, and orthostatic hypotension commonly caused by dopamine acting outside the CNS.

The continuous jejunal infusion of Duopa ensures consistent dopaminergic stimulation by maintaining stable plasma concentrations of levodopa, reducing the fluctuations (peak and trough effects) often associated with oral dosing. These fluctuations can cause motor complications such as dyskinesia and 'wearing-off' phenomena. By avoiding gastric metabolism and erratic absorption, Duopa’s delivery system markedly improves motor function and decreases 'off time' in advanced Parkinson's patients compared to oral formulations.

Clinical studies also suggest this steady dopaminergic stimulation preserves neural function and reduces non-motor symptom progression. Compared to other dopaminergic agents (e.g., dopamine agonists or MAO-B inhibitors), levodopa remains the most effective symptomatic treatment; Duopa’s unique delivery enhances its clinical utility, particularly in advanced disease with motor fluctuations.

Ongoing research explores ways to further improve the pharmacodynamics of levodopa delivery and minimize adverse motor effects; Duopa represents an important advancement facilitating personalized therapy in complex Parkinson's disease cases.

Pharmacological Actions

Dopamine precursor replacement therapy improving deficient dopaminergic neurotransmission
Inhibition of peripheral aromatic L-amino acid decarboxylase by carbidopa increasing central levodopa availability
Continuous dopaminergic stimulation through jejunal infusion reducing motor fluctuations and 'off' periods
Reduction of peripheral dopamine-related adverse effects by limiting systemic dopamine formation
Improved bioavailability and consistent plasma levodopa levels due to bypassing gastric absorption variability
Alleviation of Parkinson’s disease motor symptoms including bradykinesia, rigidity, and tremor
Maintenance of dopaminergic receptor stimulation minimizing fluctuations and dyskinesias associated with pulsatile stimulation
Therapeutic modulation of basal ganglia circuits essential for normal motor control
Potential mitigation of non-motor symptoms through steady dopaminergic delivery
Reduction of levodopa-induced peak-dose dyskinesia by controlled infusion
Enables dose titration via pump to optimize symptom control and minimize adverse effects
Facilitates management of advanced Parkinson’s disease patients with motor complications refractory to oral therapy
Acts synergistically with other CNS-active agents in Parkinsonism as part of combination therapy

Therapeutic Or Clinical Uses

Treatment of motor fluctuations in advanced Parkinson’s disease
Reduction of 'off time' periods associated with oral levodopa therapy
Management of bradykinesia, rigidity, tremor, and other motor symptoms in Parkinson’s disease
Patients who experience erratic absorption or gastric intolerance to oral carbidopa/levodopa
Improvement of quality of life by providing continuous dopaminergic stimulation
Alternative for patients with advanced Parkinson’s disease requiring complex dosing regimens
Adjunct to oral carbidopa/levodopa for nighttime symptom control
Use in patients with gastroparesis or delayed gastric emptying impacting oral medication efficacy
Short-term use via nasojejunal tube for acute symptom management or during PEG-J tube placement
To manage and mitigate dyskinesias through steady plasma levodopa levels
Indicated for patients who have experienced motor complications or fluctuations not controlled by standard oral therapy
Utilized in specialized care settings for individualized titration of dopaminergic therapy
Supports maintenance of functional mobility and activities of daily living in advanced Parkinson’s patients
Enables reduced variability in symptom control through continuous infusion delivery system
Improves medication adherence by automated continuous dosing via pump

Side Or Adverse Effects

Nausea and vomiting, particularly early in treatment or with dose escalation
Dyskinesias including involuntary, uncontrolled movements especially with higher doses
Orthostatic hypotension leading to dizziness or lightheadedness on standing
Hallucinations, confusion, and other neuropsychiatric effects such as depression or suicidal ideation
Sleep disturbances including excessive daytime sleepiness and sudden sleep onset episodes
Peripheral edema or swelling, commonly in lower extremities
Pain or irritation at the PEG-J tube insertion site including redness, swelling, warmth, or oozing
Constipation which can be ongoing or severe
Increased blood pressure in some individuals
Uncontrolled muscle movements or tics in facial muscles such as lip smacking or blinking
Allergic reactions ranging from skin rash to anaphylaxis in rare cases
Gastrointestinal symptoms including abdominal pain and stomatitis
Impulse control disorders such as pathological gambling, hypersexuality, or compulsive behaviors
Risk of melanomas or skin cancer; patients should have regular skin examinations
Possible reduction in breast milk production during lactation

Precautions

Monitor for signs of PEG-J tube infection or complications; maintain proper stoma care
Caution in patients with history of cardiac disease, high blood pressure or previous stroke
Use cautiously in patients with psychiatric disorders or history of depression
Avoid abrupt discontinuation to prevent neuroleptic malignant syndrome
Be vigilant for signs of orthostatic hypotension and counsel patients on rising slowly
Assess for impulse control disorders; monitor for pathological gambling or increased sexual urges
Avoid use with MAO inhibitors within 14 days prior due to risk of hypertensive crisis
Inform patients about potential daytime drowsiness and the risk of falling asleep during activities
Consider dietary protein intake as excessive dietary protein can impair levodopa absorption
Monitor for any onset or worsening of dyskinesia and adjust dosing accordingly
Exercise caution in patients with glaucoma or history of melanoma
Use with caution in patients with a history of peptic ulcers or gastrointestinal surgery
Caution during pregnancy and breastfeeding due to limited data on safety
Patients should be instructed to report any new or unusual urges including gambling or hypersexuality
Regular monitoring of blood pressure, mental status, and motor symptoms is recommended

Warnings

Serious side effects including infection, inflammation, or blockage at the tube insertion site require urgent medical attention
Do not use Duopa if patient has used an MAO inhibitor within the last 14 days to avoid hypertensive crisis
Risk of melanoma; patients should have regular dermatologic evaluations
Patients may experience sudden onset of sleep during daily activities; avoid driving or operating machinery until effects are known
Potential for severe orthostatic hypotension with risk of syncope and falls
Hallucinations and psychotic-like behaviors can occur, necessitating psychiatric evaluation
Use caution in patients with cardiovascular disease; monitor for arrhythmias or chest pain
Pump malfunction or tubing kinks can interrupt drug delivery leading to worsening of symptoms
Avoid abrupt discontinuation to prevent life-threatening neuroleptic malignant syndrome
Patients should be monitored for impulse control disorders which may lead to harmful behaviors
Use with caution in the elderly as they may be more sensitive to side effects
Potential for gastrointestinal complications related to PEG-J tube placement
Patients should report any unexplained fever, bleeding, or persistent gastrointestinal symptoms immediately
Do not freeze Duopa cassettes; improper storage can affect drug potency and safety
Caution with concurrent use of other CNS depressants which may potentiate sedation

Contraindication

Known hypersensitivity to carbidopa, levodopa, or any component of Duopa
Use within 14 days of treatment with monoamine oxidase inhibitors (MAOIs) such as isocarboxazid, phenelzine, or tranylcypromine
Narrow-angle glaucoma due to risk of increased intraocular pressure
Patients with undiagnosed skin lesions or melanoma
Inability or unwillingness to undergo surgical placement of PEG-J tube
History of hypersensitivity reactions or anaphylaxis to levodopa/carbidopa formulations
Concomitant use with nonselective MAO inhibitors
Patients with severe gastrointestinal obstruction or disorders contraindicating PEG-J tube placement
Severe cardiovascular conditions where dopaminergic stimulation is deemed unsafe
Patients who cannot comply with the technical and monitoring requirements of pump therapy

Drug Interactions

MAO inhibitors (nonselective) – risk of hypertensive crisis if used with Duopa within 14 days
Dopaminergic antagonists such as antipsychotics (e.g., haloperidol) – may reduce effectiveness
Metoclopramide and other dopamine antagonists – may lessen therapeutic effects
Iron supplements – may decrease levodopa absorption; separate dosing by several hours
Antihypertensive medications – levodopa may counteract effects leading to blood pressure variability
Drugs causing CNS depression (opioids, benzodiazepines, muscle relaxants) – may potentiate sedation and sleepiness
Vitamin B6 (high doses) – may increase peripheral metabolism of levodopa, reducing efficacy
Other drugs affecting cytochrome P450 enzymes may indirectly alter levodopa metabolism
Certain antidepressants – risk of serotonin syndrome or altered dopamine metabolism
Phenytoin or other antiepileptic drugs – possible effects on dopaminergic drug levels
Concomitant use with drugs that prolong QT interval requires caution due to potential cardiac effects
Ferrous sulfate and multi-vitamin supplements containing iron can interfere with drug absorption
Drugs used for hypertension and cardiac conditions require monitoring for additive hypotensive or arrhythmic effects
Concomitant use with herbal supplements affecting CNS neurotransmission may alter clinical response
Consult healthcare providers regarding all prescription, over-the-counter, and herbal drugs before initiation

Preparations Of The Drug

Duopa enteral suspension gel in single-use plastic cassettes containing carbidopa 4.63 mg and levodopa 20 mg per mL
Each cassette designed for 16-hour infusion use with the CADD-Legacy 1400 portable pump
Suspension intended for administration through PEG-J tube directly into the jejunum or short-term via naso-jejunal tube
Cassettes are frozen (-20°C) during storage and require controlled thawing in refrigeration before use
Single-use cassettes should be brought to room temperature for 20 minutes before administration to ensure consistent dosing
Packaged in light-protective carton to maintain drug stability prior to use
Includes accessory caps and tubing connectors compatible with the infusion pump system
Each cassette is vacuum-sealed to maintain sterility and prevent contamination
Contains excipients that maintain suspension stability and prevent sedimentation
Packaging includes patient instruction leaflets detailing administration, pump use, and stoma care
Not intended for oral or intravenous administration; strictly for enteral infusion via designated pumps
Compatible proprietary infusion pump and tubing systems must be used to ensure proper delivery and dosing accuracy
Preparation protocols advise against shaking or agitating suspension excessively to prevent foam formation
Disposed of as single-use unit after completion of 16-hour infusion period to maintain sterility and dosing precision
Stored and dispensed under medical supervision due to specialized delivery and handling requirements